Products
Heberprot-P is a Cuban drug developed in Havana am and has been on the market since 2007. It is now available as an injectable in numerous countries. It is not currently registered in many countries.
Structure and properties
Heberprot-P contains recombinant human epidermal growth factor (rhEGF), a comparatively small protein with 53 amino acids and a molecular weight of 6,045 kDa.
Effects
Epidermal growth factor rhEGF has wound healing-promoting properties. EGF promotes cell growth, cell differentiation, cell proliferation, and wound granulation. Treatment accelerates healing and reduces the risk of recurrence and amputation.
Indications
For the treatment of ulceration in diabetic foot syndrome.
Dosage
According to the SmPC. The drug is injected peri-lesionally and intralesionally.
Contraindications
- Hypersensitivity
- Cancer
- Diabetic coma, ketoacidosis
For complete precautions, see the drug label.
Interactions
Concomitant use of other topical medications is not recommended.
Adverse effects
The most common possible adverse effects include local reactions such as pain and a burning sensation. Furthermore, infections, fever, and chills may occur.
